Senores Pharmaceuticals Limited - Due diligence report

A 360° intelligence report on Senores Pharmaceuticals: trust score, financial health, credit view, compliance, directors, growth and distres…

2017-12-26 Ahmedabad, Gujarat Active Listed Active Compliant
Connect MCP
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Senores Pharmaceuticals — 360° Intelligence Report

Generated from MCA filings & public records
85/100
Trust Score
Low Risk

Senores Pharmaceuticals is assessed as Low Risk with a Trust Score of 85/100. Senores Pharmaceuticals is an active public limited indian non-government company incorporated in 2017, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 22 Nov 2026 from the latest processed filings. Senores Pharmaceuticals Limited snapshot & full profile →

Overall Assessment CautionWeakNeutralGoodStrong Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
85/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
70/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
80/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Consolidated · 0 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 80/100 Low Risk
  • Moderate gearing (D/E 38%).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 12 open ( 48.0 cr ) · 4 satisfied ( 12.5 cr ).

Banking relationships (from registered charges)
LenderChargesAmount
Hdfc Bank Limited10 48.0 cr
Others5 48.0 cr
Axis Bank Limited1 48.0 cr
Compliance Score: 70/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2025).
  • 2 auditor resignation(s) filed - latest: Parikh & Majmudar on 2024-02-06.
  • Delayed payments to MSME suppliers disclosed (10 disclosure(s)).
  • 2 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SANJAY SHAILESHBHAI MAJMUDAR 01234567 Director 01/04/2018 6 yrs Approved
ASHOKBHAI VIJAYSINH BAROT 01234567 Director 01/04/2018 6 yrs Approved
SWAPNIL JATINBHAI SHAH 01234567 Director 01/04/2018 6 yrs Approved
Naresh Bansilal Shah 01234567 Director 01/04/2018 6 yrs Approved
Hemanshu Nitinchandra Pandya 01234567 Director 01/04/2018 6 yrs Approved
Chetan Bipinchandra Shah 01234567 Director 01/04/2018 6 yrs Approved
KALPIT RAJESH GANDHI 01234567 Director 01/04/2018 6 yrs Approved
UDAYAN DILEEP CHOKSI 01234567 Director 01/04/2018 6 yrs Approved
JITENDRA BABULAL SANGHVI 01234567 Director 01/04/2018 6 yrs Approved
ARPIT DEEPAKKUMAR SHAH 01234567 Director 01/04/2018 6 yrs Approved
DEVAL RAJNIKANT SHAH 01234567 Director 01/04/2018 6 yrs Approved
MANJULA DEVI SHROFF 01234567 Director 01/04/2018 6 yrs Approved
Deval Rajnikant Shah 01234567 Director 01/04/2018 6 yrs Approved
  • 13 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2025 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
10 allotment(s) · 5 transfer(s)

Promoters hold the largest single block of equity - exact percentages are part of the full report.

Group entityRelationship% held
RATNATRIS PHARMACEUTICALS PRIVATE LIMITED Subsidiary Company 74.00%

Key managerial personnel: SWAPNIL JATINBHAI SHAH (Managing Director) · Chetan Bipinchandra Shah (Whole-time director) · DEVAL RAJNIKANT SHAH (Whole-time director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 3 year(s).
Latest year revenue grew 2.1x.
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 8 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
12 open charge(s) registered - assets are encumbered.
2 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence80/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment82/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 12 open charge(s) already registered.
  • Compliance record supports lending.
Investor view92/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
29 Jun 2026
Charge created
Others - 30.00 Lakh
22 Jun 2026
Charge created
Hdfc Bank Limited - 32.42 Lakh
12 Jun 2026
Charge created
Hdfc Bank Limited - 2.56 cr
07 May 2026
Charge created
Others - 35.00 cr
12 Mar 2026
Charge created
Hdfc Bank Limited - 27.23 Lakh
13 Nov 2025
Charge created
Hdfc Bank Limited - 23.00 Lakh
18 Sep 2025
Last AGM held
Annual general meeting
26 Jun 2025
Charge created
Hdfc Bank Limited - 44.60 Lakh
02 May 2025
Charge created
Hdfc Bank Limited - 35.10 Lakh
31 Mar 2025
Latest balance sheet
Filed with ROC
17 Mar 2025
Charge satisfied
Others
13 Feb 2025
Charge created
Others - 45.00 cr
12 Feb 2025
Charge satisfied
Hdfc Bank Limited
07 Dec 2024
Charge created
Hdfc Bank Limited - 11.29 Lakh
05 Oct 2024
Charge created
Others - 43.55 cr
10

Key Observations

Auto-generated from the data above
Revenue grew 61% over the last 3 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
13 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold the largest single block of equity as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 10 security allotment(s) - amounts available in the full report.
49 overseas direct investment(s) (ODI) on record - international footprint.
Approximately 2 employees on EPFO payroll records.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Wanbury L51900MH1988PLC048455 New Mumbai, Maharashtra, India
Agrocel U24210GJ1985PTC007569 Bhachau, Gujarat, India
Sudeep Pharma Limited L24231GJ1989PLC013141 Baroda, Gujarat, India
Panacea Biotec L33117PB1984PLC022350 Lalru, Punjab, India
Kopran L24230MH1958PLC011078 Mumbai, Maharashtra, India
Ind Swift L24232CH1995PLC015553 Chandigarh, Chandigarh, India
Omniactive Health Technologies U24230MH2003PLC141898 Mumbai, Maharashtra, India
Minimalist U36999RJ2018PTC061104 Jaipur, Rajasthan, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Senores Pharmaceuticals before audits and certifications: compliance score 70/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Senores Pharmaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 80/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Senores Pharmaceuticals - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 85/100, distress signals and MSME payment-delay disclosures - know whether Senores Pharmaceuticals pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Senores Pharmaceuticals - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Senores Pharmaceuticals an active company?

Senores Pharmaceuticals has MCA status “Active” with a compliance score of 70/100 (Moderate).

Is Senores Pharmaceuticals financially healthy?

Senores Pharmaceuticals has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Senores Pharmaceuticals?

Its overall Trust Score is 85/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Senores Pharmaceuticals?

Promoters hold the largest single block of equity - exact percentages are in the full report. 13 active director(s) are on record.

Does Senores Pharmaceuticals have loans or charges against its assets?

12 open charge(s) are registered against its assets, and 4 earlier charge(s) stand satisfied.

Is Senores Pharmaceuticals up to date with its ROC filings?

Balance sheet slightly behind (Mar 2025). Overall compliance score: 70/100 (Moderate).

Is it risky to lend to Senores Pharmaceuticals?

Its Credit Risk Score is 80/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.